ClearPoint Neuro, Inc. $CLPT Shares Purchased by Lane Generational LLC

Lane Generational LLC grew its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 20.7% during the third quarter, Holdings Channel.com reports. The firm owned 311,885 shares of the company’s stock after acquiring an additional 53,458 shares during the period. ClearPoint Neuro accounts for about 5.6% of Lane Generational LLC’s portfolio, making the stock its 6th largest position. Lane Generational LLC’s holdings in ClearPoint Neuro were worth $6,796,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Millennium Management LLC increased its stake in shares of ClearPoint Neuro by 156.3% in the first quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after buying an additional 452,043 shares in the last quarter. Goldman Sachs Group Inc. increased its position in ClearPoint Neuro by 98.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after acquiring an additional 127,823 shares in the last quarter. MGO One Seven LLC raised its stake in shares of ClearPoint Neuro by 9.6% in the second quarter. MGO One Seven LLC now owns 17,949 shares of the company’s stock worth $214,000 after acquiring an additional 1,569 shares during the last quarter. AlphaQuest LLC raised its stake in shares of ClearPoint Neuro by 433.5% in the second quarter. AlphaQuest LLC now owns 9,411 shares of the company’s stock worth $112,000 after acquiring an additional 7,647 shares during the last quarter. Finally, Pekin Hardy Strauss Inc. lifted its position in shares of ClearPoint Neuro by 3.6% during the second quarter. Pekin Hardy Strauss Inc. now owns 50,575 shares of the company’s stock worth $604,000 after purchasing an additional 1,750 shares in the last quarter. Institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Stock Performance

Shares of ClearPoint Neuro stock opened at $12.93 on Friday. The firm has a fifty day moving average of $14.12 and a two-hundred day moving average of $15.26. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.56 and a current ratio of 6.37. The stock has a market capitalization of $367.47 million, a price-to-earnings ratio of -15.39 and a beta of 0.91. ClearPoint Neuro, Inc. has a 52 week low of $9.76 and a 52 week high of $30.10.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $5.36 million during the quarter, compared to the consensus estimate of $9.60 million. ClearPoint Neuro had a negative return on equity of 114.28% and a negative net margin of 67.40%. As a group, equities research analysts predict that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Wall Street Analyst Weigh In

CLPT has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Wednesday, January 21st. Wall Street Zen downgraded ClearPoint Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ClearPoint Neuro presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Insider Activity at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 2,943 shares of the stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $15.57, for a total value of $45,822.51. Following the sale, the chief executive officer directly owned 214,116 shares in the company, valued at $3,333,786.12. This trade represents a 1.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.97% of the stock is currently owned by company insiders.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.